At the EHRA 2019 congress in Lisbon, Professor Robert Storey (Professor of Cardiology, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK) joins us to discuss the latest research from the AUGUSTUS study and the challenges faced by patients with atrial fibrillation and acute coronary syndrome.
Filmed at EHRA 2019, Lisbon.
Speaker’s Disclosures: Dr Robert Storey has received consultancy fees, honoraria and/or research grants from AstraZeneca, Bayer, Bristol Myers, Haemonetics, Idorsia, Novartis, Squibb/Pfizer, PlaqueTec and Thromboserin.
1. Please explain the challenges of managing antithrombotic therapy in patients with atrial fibrillation who have concomitant acute coronary syndrome or are undergoing percutaneous coronary intervention. (0:14)
2. What is the potential role of non-vitamin K antagonist oral anticoagulants (NOACs) in managing stroke risk in these patients? (1:31)
3. Are the AUGUSTUS findings consistent with other evidence examining the role of NOACs in managing stroke risk in patients with atrial fibrillation and acute coronary syndrome? (0:14)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Atrial Fibrillation
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Suneet Mittal, AF Symposium 2021: Atrial Fibrillation in the Post-COVID-19 Environment
We spoke to Dr Suneet Mittal (Director of Electrophysiology, The Valley Hospital, Ridgewood, NJ, USA) about the workflow innovations for atrial fibrillation ablation in the post-COVID-19 environment. Questions What have been the main challenges to atrial fibrillation (AF) ablation workflow during the COVID-19 pandemic? (0.14) What workflow innovations have been created and incorporated over the […]
Hugh Calkins, AF Symposium 2021: the STOP Persistent AF Clinical Trial
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about the STOP Persistent AF Clinical Trial (NCT03012841). Questions: Could you tell us a little about the aims and design of the STOP Persistent AF clinical trial? (0.13) What were the findings of the study? (0.43) What are their implications for clinical practice? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!